Abstract | INTRODUCTION:
Allergic rhinitis (AR) is a high-prevalence disease, sustained by an IgE-triggered reaction with histamine release, followed by an inflammatory response which involves cells, mediators, cytokines and adhesion molecules. According to its duration, AR can be either intermittent or persistent. In the persistent form, the inflammatory component usually predominates. AREAS COVERED: EXPERT OPINION: In the last years there have been very few innovative approaches to optimize the management of AR. These include new histamine receptor antagonists, combination therapy and strategies to selectively block relevant signaling pathways of the allergic reaction. Some more promising advances have been shown for allergen immunotherapy, where a number of new strategies are currently under development.
|
Authors | Giovanni Passalacqua, Giorgio Ciprandi |
Journal | Expert opinion on emerging drugs
(Expert Opin Emerg Drugs)
Vol. 17
Issue 4
Pg. 543-53
(Dec 2012)
ISSN: 1744-7623 [Electronic] England |
PMID | 23186314
(Publication Type: Journal Article, Review)
|
Chemical References |
- Allergens
- Histamine Antagonists
- Immunoglobulin E
- Histamine
|
Topics |
- Allergens
(immunology)
- Animals
- Drug Design
- Histamine
(metabolism)
- Histamine Antagonists
(pharmacology, therapeutic use)
- Humans
- Immunoglobulin E
(immunology)
- Immunotherapy
(methods)
- Rhinitis, Allergic, Perennial
(drug therapy, immunology, therapy)
- Signal Transduction
(drug effects)
|